Ionis Pharmaceuticals, Inc. (IONS) Earns “Hold” Rating from Stifel Nicolaus

Stifel Nicolaus reissued their hold rating on shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in a research note issued to investors on Tuesday morning.

IONS has been the topic of several other reports. TheStreet raised shares of Ionis Pharmaceuticals from a d+ rating to a c- rating in a research note on Wednesday, July 5th. Leerink Swann reissued an outperform rating and issued a $45.00 price target (down from $47.00) on shares of Ionis Pharmaceuticals in a research note on Wednesday, May 17th. Needham & Company LLC reissued a buy rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, August 8th. Finally, Evercore ISI assumed coverage on shares of Ionis Pharmaceuticals in a research note on Wednesday, August 16th. They issued an outperform rating and a $65.00 price target on the stock. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $49.31.

Shares of Ionis Pharmaceuticals (NASDAQ IONS) traded up 0.63% during mid-day trading on Tuesday, hitting $58.74. 302,233 shares of the stock traded hands. Ionis Pharmaceuticals has a 12 month low of $24.58 and a 12 month high of $60.01. The company has a market cap of $7.30 billion, a P/E ratio of 282.40 and a beta of 3.13. The firm has a 50 day moving average of $51.14 and a 200 day moving average of $48.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). The business had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The business’s quarterly revenue was up 170.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.47) earnings per share. Equities analysts anticipate that Ionis Pharmaceuticals will post ($0.17) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Ionis Pharmaceuticals, Inc. (IONS) Earns “Hold” Rating from Stifel Nicolaus” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/15/ionis-pharmaceuticals-inc-ions-earns-hold-rating-from-stifel-nicolaus.html.

In other news, Chairman Stanley T. Crooke sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $55.35, for a total value of $608,850.00. Following the sale, the chairman now directly owns 48,014 shares of the company’s stock, valued at approximately $2,657,574.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Stanley T. Crooke sold 16,500 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $52.45, for a total transaction of $865,425.00. Following the completion of the sale, the chairman now directly owns 53,014 shares in the company, valued at $2,780,584.30. The disclosure for this sale can be found here. Insiders sold a total of 55,309 shares of company stock worth $2,997,692 over the last three months. Insiders own 1.86% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC grew its holdings in shares of Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock valued at $109,000 after purchasing an additional 800 shares in the last quarter. Hanseatic Management Services Inc. grew its holdings in shares of Ionis Pharmaceuticals by 1.2% in the second quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after purchasing an additional 41 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares in the last quarter. WFG Advisors LP grew its holdings in shares of Ionis Pharmaceuticals by 77.2% in the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after purchasing an additional 1,655 shares in the last quarter. Finally, Westpac Banking Corp acquired a new position in shares of Ionis Pharmaceuticals in the first quarter valued at approximately $171,000. Hedge funds and other institutional investors own 89.33% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply